Phase III study with finerenone in Chronic Heart Failure

• Research type

  Research Study

• Full title

  A multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to evaluate the efficacy and safety of finerenone compared to eplerenone on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or both.

• IRAS ID

  188589

• Contact name

  Iain Squire

• Contact email

  is11@leicester.ac.uk

• Sponsor organisation

  Bayer PLC

• Eudract number

  2015-002168-17

• Duration of Study in the UK

  2 years, 11 months, 25 days

• Research summary

  Efficacy and safety of finerenone in subjects with chronic heart failure at high risk for recurrent heart failure decompensation.

• REC name

  West Midlands - Edgbaston Research Ethics Committee

• REC reference

  15/WM/0365

• Date of REC Opinion

  30 Oct 2015

• REC opinion

  Further Information Favourable Opinion